Liquidia (NASDAQ:LQDA) Insider Scott Moomaw Sells 831 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 831 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $32.19, for a total value of $26,749.89. Following the completion of the sale, the insider owned 154,506 shares of the company’s stock, valued at $4,973,548.14. This represents a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Scott Moomaw also recently made the following trade(s):

• On Monday, October 13th, Scott Moomaw sold 4,900 shares of Liquidia stock. The stock was sold at an average price of $23.41, for a total value of $114,709.00.

Liquidia Stock Performance

Shares of LQDA stock opened at $30.79 on Wednesday. The stock has a market cap of $2.68 billion, a PE ratio of -21.38 and a beta of 0.48. The stock has a 50-day moving average of $25.57 and a 200-day moving average of $21.56. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. Liquidia Corporation has a one year low of $10.37 and a one year high of $32.80.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.41. The company had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. Liquidia’s revenue for the quarter was up 1106.7% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

A number of large investors have recently bought and sold shares of the company. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia in the third quarter valued at approximately $30,000. NewEdge Advisors LLC bought a new position in Liquidia in the second quarter valued at $25,000. Quarry LP acquired a new stake in Liquidia in the 1st quarter valued at $79,000. Steward Partners Investment Advisory LLC increased its stake in Liquidia by 24.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after buying an additional 1,200 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after buying an additional 4,927 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 target price on shares of Liquidia in a report on Monday, November 3rd. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Raymond James Financial reiterated a “strong-buy” rating and issued a $47.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Finally, Wells Fargo & Company began coverage on shares of Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.56.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).